BioGenome Therapeutics is an immunotherapy company developing methodologies to modulate genes and MiR pathways involved in cellular protection, repair and immune response.

What medical and scientific applications does C.A.R.E. RadioImmunotherapy provide?

With direct applications to cancer treatment, Diabetes, cardiac, Rheumatoid Arthritis, Alzheimer’s, and other inflammatory diseases, BioGenome Therapeutics’s C.A.R.E RadioImmunotherapySM modulates DNA and Micro Interference RNA pathways to counteract, and potentially cure diseases and its progression.

BioGenome Therapeutics’s technology is focused on modulating genes and proteins at the cellular level as part of a natural adaptive response that protects healthy cells from damage and increases the killing effect of cancer and other inflammatory diseases.  By identifying and re-creating the Micro Interference Pathways involved in the immune response, BioGenome Therapeutics is working towards a novel drug therapy and delivery system that will impact all proteins involved in the disease vs. the current immunotherapy protocol of impacting one protein at a time.  Addressing all proteins in the pathway has the unique ability to reduce treatment side effects while dramatically increasing effectiveness.

What are the primary benefits that research has validated to date?

What is the research behind C.A.R.E. RadioImmunotherapy℠?

Dr. Richard Blankenbecler, a world-renowned professor of Theoretical Physics at Stanford University’s SLAC National Accelerator Laboratory, developed and patented the process to activate latent genes that can be utilized in cancer, neurological, autoimmune, and inflammatory diseases. His discoveries and patents are based on $250 million of research over 16 years, sponsored by the U.S. Department of Energy’s Office of Science, Low Dose Radiation Research program.

The D.O.E. research validates that low levels of radiation are not only safe, but beneficial to humans.

At low doses of radiation, all organisms have cellular repair and response mechanisms that can keep adverse health effects from occurring, something that has evolved as life evolved (PNAS 2011).  BioGenome Therapeutics was conceived when Dr. Blankenbecler applied this knowledge to solve untreated medical dilemmas.

Pre-clinical research has shown that C.A.R.E. RadioImmunotherapy (patented as CARE Pre-Dose Therapy) activates genes in the healthy tissue that perform cellular repair. It might seem counter-intuitive that any amount of radiation can be beneficial however, the patented C.A.R.E. RadioImmunotherapy has been proven to make healthy cells more resistant to subsequent cancer treatments that are toxic to healthy tissue, such as radiation and drug therapy …Read More About Our Research

How does it work?

C.A.R.E. RadioImmunotherapy modulates the genomic and proteomic response to “insults” at the cellular level caused by cancer treatment toxicity, neurological, autoimmune, or inflammatory diseases. The C.A.R.E. RadioImmunotherapy protocol is used in combination with standard or personalized disease treatment to produce the best possible outcomes.

  • Prior to drug or radiation treatment, low levels of radiation are given to healthy tissue, activating genes involved in cellular repair.
  • The amount of pre-dose radiation is small; less than the equivalent of a full body CT Scan
  • The genes and proteins that are activated in the DNA are involved in delaying cell cycling and repairing toxic and inflammatory insults to the cells.
  • Within 24-72 hours of administering the C.A.R.E. RadioImmunotherapy, Standard or personalized disease treatment proceeds.

Recent Articles

It has been generally accepted that both natural and man-made sources of ionizing radiation contribute to human exposure...
Oriana Sousa, 28, who lives in Marinha Grande, Portugal, had a rare, aggressive form of ovarian cancer. Traditional trea...
The science of using immunotherapy to treat cancer is advancing rapidly, marked by the National Cancer Institute’s rec...
The science of using immunotherapy to treat cancer is advancing rapidly, marked by the National Cancer Institute’s rec...